Posts for Ticker ‘MAKO’

Top Pre-Market Analyst Upgrades (AMGN, CPLP, DRIV, DSX, DNA, GNK, MAKO)

These are some of the top upgrades we are seeing from Wall Street analysts this morning:

  • Amgen (AMGN) Raised to Outperform at William Blair.
  • Capital Product Partners (CPLP) Started as Outperform at Oppenheimer.
  • Digital River (DRIV) Raised to Neutral at Goldman Sachs.
  • Diana Shipping (DSX) Started as Outperform at Oppenheimer.
  • Genentech (DNA) Raised to Outperform at William Blair.
  • Genco Ship & Trading (GNK) Started as Outperform at Oppenheimer.
  • Mako Surgical (MAKO) Started as Buy at Piper Jaffray.

Jon C. Ogg
October 2, 2008

Posted on: October 2, 2008 – 7:16 am in Analyst Calls, , , , , , ,

Top 10 Pre-Market Analyst Calls (AYR, ARST, GLS, HCBK, JRN, MAKO, PFCB, TLM, WAT, WW)

These are the top analyst upgrades and downgrades that 247WallSt.com is focusing on in pre-market trading this Wednesday morning:

  • Aircastle (NYSE: AYR) Downgraded to Neutral from Overweight at JPMorgan.
  • ArcSight (NASDAQ: ARST) started as Outperform at Wachovia; started as Equal Weight at Lehman Brothers.
  • Genesis Lease (NYSE: GLS) Downgraded to Neutral from overweight at JP Morgan.
  • Hudson City Banc (NASDAQ: HCBK) Downgraded to Market Perform from Outperform at FBR.
  • Journal Commun (NYSE: JRN) started as Outperform at Bear Stearns.
  • MAKO Surgical (NASDAQ: MAKO) Started as Market Perform at Wachovia; Started as Overweight at JPMorgan.
  • P.F. Chang’s (NASDAQ: PFCB) Downgraded to Underperform From Market Perform at FBR.
  • Talisman Energy (NYSE:TLM) raised to Buy from Hold at Citigroup.
  • Waters (NYSE: WAT) Raised To Overweight From Neutral at JPMorgan.
  • Watson Wyatt (NYSE: WW) raised to Buy from Hold at UBS.

Jon C. Ogg
March 26, 20008

Posted on: March 26, 2008 – 6:05 am in Analyst Calls, , , , , , , , , ,

MAKO Surgical Slashes IPO Terms (MAKO)

MAKO Surgical originally filed to come public back in September 2007.  It filed to sell up to $86.25 million in securities.  Recently it had indicated a price range of $14 to $16 per share for a 5.1 million share IPO.  Apparently market conditions won’t support anywhere close to that.

The new price target range for this IPO is $10 to $11 per share for this IPO.  The company makes advanced devices for minimally invasive knee surgeries.  It is also a revenue generating company, and frankly is in a sector that should have supported a normal IPO.

We still show that JPMorgan, Morgan Stanley, Cowen & Co. and Wachovia are the underwriters for this and the ticker will still be "MAKO" on NASDAQ.

If you have followed our IPO index here internally you will note how many withdrawals have happened in IPO’s of late.

Jon C. Ogg
February 14, 2008

Posted on: February 14, 2008 – 7:35 am in IPOs,

IPO Filing: MAKO Surgical Corp.

MAKO Surgical Corp. has filed to come public in an initial public offering and for nominal filing purposes, it lists that it will sell up to $86.25 million in securities.  MAKO is taking the "MAKO" ticker on NASDAQ.  The lead underwriters are J.P.Morgan and Morgan Stanley, and co-managers are listed as Cowen & Co. and Wachovia.

The company appears to be a revlutionary robotic device maker for less invasive knee surgery.  It markets an advanced robotic solution and implants for minimally invasive orthopedic knee procedures under the name MAKOplasty, frequently to early to mid-stage osteoarthritic knee disease. MAKOplasty is FDA-cleared for its Haptic Guidance System, a interactive haptic robotics platform that utilizes tactile-guided robotics and patient-specific visualization.  Unlike conventional knee replacement surgery, which requires extraction and replacement of the entire joint, MAKOplasty optimizes localized resurfacing of the specific diseased compartment of the joint by using the robotics technology to achieve consistently reproducible precision and optimal implant placement and alignment.

According to Frost &  Sullivan, the total U.S. market for total knee replacement and knee resurfacing procedures was greater than $2.7 billion in 2006, and is expected to grow at approximately 8% per year to more than $4.6 billion by 2013.  MAKO’s total sales in 2006 were $62.57 million and its loss attributable to shareholders was listed as $12.493 million (-$10.8 million from operations), but over 90% of that came at the end of the year after this started to be marketd.  In the first 6-months of 2007, MAKO generated $205.94 million in revenues and net loss for shareholders was listed as  $9.219 million (-$7.9 million from operations).

Jon C. Ogg
September 19, 2007

Posted on: September 19, 2007 – 8:25 am in IPOs, Medical, , , , , ,